Advertisement

Related Videos

Sarah Yim, MD, on Clinical Development of Biosimilars: Lessons for Interventional Pharmacoeconomics

Varsha Gandhi, PhD, on Ibrutinib

Russell Szmulewitz, MD, on Alternative Dosing of Abiraterone in Prostate Cancer: Pharmacoeconomic Proof of Concept

David T. Rubin, MD, on Biosimilars for Inflammatory Bowel Disease

Gary L. Rosner, ScD, on Bayesian Non-Inferiority

Advertisement

Advertisement




Sep
16
Today In Oncology
Ivonescimab Significantly Improves Overall Survival vs Pembrolizumab in PD-L1–Positive Advanced NSCLC
Izalontamab Brenitecan Active in Previously Treated EGFR NSCLC
DAROL Examines Darolutamide With Lipid-Modifying Agents in Nonmetastatic Castration-Resistant Prostate Cancer
MAVERICK Trial Supports Brain MRI Surveillance Alone as Standard of Care for SCLC
New Executive Director of the Duke Cancer Institute Named
View More 
Advertisement
© 2026 HSP News Service, L.L.C.
Conexiant Oncology Logo